Who
K. Gary Barnette
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Veru; Vice President, Gtx Inc /de/.
In numbers
- Trades disclosed
- 23
- Buys
- 4
- Sells
- 1
- Bought
- $162K
- Sold
- $1.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Jan 2006
- Last trade
- 13 Aug 2026
- Last filed
- 17 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 17 Aug 2026 | VERU VeruBiotechnology | SEC FORM 4 Bought | $4,8421,800 at $2.69 | filing |
| 13 Aug 2026filed 17 Aug 2026 | VERU VeruBiotechnology | SEC FORM 4 Bought | $4,8421,800 at $2.69 | filing |
| 4 May 2026filed 6 May 2026 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 5 Dec 2025filed 9 Dec 2025 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 6 May 2025filed 8 May 2025 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —104,000 at $0.00 | filing |
| 24 May 2024filed 24 May 2024 | VERU VeruBiotechnology | SEC FORM 4 Bought | $6,7005,000 at $1.34 | filing |
| 7 May 2024filed 9 May 2024 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —102,000 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Nov 2022filed 4 Nov 2022 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —98,000 at $0.00 | filing |
| 22 Apr 2022filed 25 Apr 2022 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 3 Nov 2021filed 5 Nov 2021 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —134,800 at $0.00 | filing |
| 16 Dec 2020filed 18 Dec 2020 | VERU VeruBiotechnology | SEC FORM 4 Sold | $1.1M100,000 at $10.65 | filing |
| 13 Nov 2020filed 17 Nov 2020 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 14 Nov 2019filed 18 Nov 2019 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 14 Nov 2019filed 18 Nov 2019 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,808 at $0.00 | filing |
| 13 May 2019filed 21 May 2019 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —99,000 at $0.00 | filing |
| 18 Dec 2018filed 19 Dec 2018 | VERU VeruBiotechnology | SEC FORM 4 Bought | $76K50,000 at $1.51 | filing |
| 17 Dec 2018filed 19 Dec 2018 | VERU VeruBiotechnology | SEC FORM 4 Bought | $71K50,000 at $1.41 | filing |
| 4 Sep 2018filed 5 Sep 2018 | VERU Veruoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
News
Financial Contrast: Unicycive Therapeutics (NASDAQ:UNCY) and Veru (NASDAQ:VERU)VERU · themarketsdaily.com · 20 Oct 2026
0 headlines in the last 90 days name K. Gary Barnette; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.